VAC Bioburden Wound Care Assessment
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to compare the microbiologic burden and need for further operative debridement of patients undergoing primary surgical debridement of infected tissue, soft tissue abscesses, or traumatic wounds of the upper and lower extremity.
Full description
Bacterial bio-burden as measured by quantitative microbial PCR prior to debridement, immediately following initial debridement, after 2 days of VAC veraflo (or conventional VAC) therapy, and at the time of repeat operative debridements, if needed. We will use the MicroGen PCR platform (DBA Microgen Diagnostics, LLC, Lubbock, TX.) to report on the bacterial burden (reported on a log scale of bacteria per gram) present at the time of debridement. Our goal is to be able to assess the bioburden quantitatively at each time point to discern a change.
Exploratory outcomes to be measured: number of operative debridements required prior to reconstruction, number of days until final reconstruction, number of days until decision is made by surgeon that further debridements are no longer necessary, length of hospital stay, wound surface area will be monitored from enrollment through when the veraflo is removed. This is likely a 3-month interval.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- 18+yo with an injury or infection of the upper or lower extremity for which surgical debridement (in the operating room) followed by VAC application is planned.
Exclusion criteria
- Patient with wounds distal to the ankle.
Trial design
Primary purpose
Allocation
Interventional model
Masking
5 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Suhail Mithani
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal